Alexis Elbaz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2262426/publications.pdf

Version: 2024-02-01

4117 12330 32,905 183 69 175 citations h-index g-index papers 191 191 191 48303 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2197-2223.	13.7	7,061
2	Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2163-2196.	13.7	6,376
3	Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 459-480.	10.2	2,625
4	Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2018, 17, 939-953.	10.2	1,573
5	Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2129-2143.	13.7	1,013
6	Timing of onset of cognitive decline: results from Whitehall II prospective cohort study. BMJ: British Medical Journal, 2012, 344, d7622-d7622.	2.3	610
7	Collaborative Analysis of \hat{l} ±-Synuclein Gene Promoter Variability and Parkinson Disease. JAMA - Journal of the American Medical Association, 2006, 296, 661.	7.4	467
8	A calcium channel mutation causing hypokalemic periodic paralysis. Human Molecular Genetics, 1994, 3, 1415-1419.	2.9	319
9	Risk tables for parkinsonism and Parkinson's disease. Journal of Clinical Epidemiology, 2002, 55, 25-31.	5.0	304
10	Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case–control study. Lancet Neurology, The, 2011, 10, 898-908.	10.2	294
11	Epidemiology of Parkinson's disease. Revue Neurologique, 2016, 172, 14-26.	1.5	292
12	Restoration of normal motor control in Parkinson's disease during REM sleep. Brain, 2007, 130, 450-456.	7.6	287
13	Slow walking speed and cardiovascular death in well functioning older adults: prospective cohort study. BMJ: British Medical Journal, 2009, 339, b4460-b4460.	2.3	274
14	Mapping of the hypokalaemic periodic paralysis (HypoPP) locus to chromosome 1q31–32 in three European families. Nature Genetics, 1994, 6, 267-272.	21.4	257
15	Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study. BMJ: British Medical Journal, 2017, 357, j2709.	2.3	248
16	Obesity trajectories and risk of dementia: 28 years of followâ€up in the Whitehall II Study. Alzheimer's and Dementia, 2018, 14, 178-186.	0.8	240
17	Common Carotid Artery Intima-Media Thickness and Brain Infarction. Circulation, 2000, 102, 313-318.	1.6	239
18	Professional exposure to pesticides and Parkinson disease. Annals of Neurology, 2009, 66, 494-504.	5.3	234

#	Article	IF	Citations
19	UCHL1 is a Parkinson's disease susceptibility gene. Annals of Neurology, 2004, 55, 512-521.	5.3	227
20	Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's. Annals of Neurology, 2016, 80, 674-685.	5.3	226
21	Association Between Questionnaire- and Accelerometer-Assessed Physical Activity: The Role of Sociodemographic Factors. American Journal of Epidemiology, 2014, 179, 781-790.	3.4	225
22	Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study. Lancet, The, 1999, 354, 281-286.	13.7	224
23	Common variants at 12q14 and 12q24 are associated with hippocampal volume. Nature Genetics, 2012, 44, 545-551.	21.4	212
24	Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology, 2012, 78, 417-420.	1.1	203
25	Risk of cardiovascular disease morbidity and mortality in frail and pre-frail older adults: Results from a meta-analysis and exploratory meta-regression analysis. Ageing Research Reviews, 2017, 35, 63-73.	10.9	182
26	Survival Study of Parkinson Disease in Olmsted County, Minnesota. Archives of Neurology, 2003, 60, 91.	4.5	178
27	Impact of Smoking on Cognitive Decline in Early Old Age. Archives of General Psychiatry, 2012, 69, 627-35.	12.3	176
28	The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. Blood, 2000, 95, 586-591.	1.4	175
29	CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease. Annals of Neurology, 2004, 55, 430-434.	5.3	175
30	Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology, 2018, 91, e189-e201.	1.1	175
31	Predicting cognitive decline. Neurology, 2013, 80, 1300-1306.	1.1	169
32	Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 952-957.	1.9	169
33	Interleukin-6 and C-reactive protein as predictors of cognitive decline in late midlife. Neurology, 2014, 83, 486-493.	1.1	167
34	Global, regional, and national burden of motor neuron diseases 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2018, 17, 1083-1097.	10.2	163
35	Structural abnormalities in the cerebellum and sensorimotor circuit in writer's cramp. Neurology, 2007, 69, 376-380.	1.1	161
36	Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson's disease in the European population. Human Molecular Genetics, 2011, 20, 615-627.	2.9	155

#	Article	IF	Citations
37	Midlife type 2 diabetes and poor glycaemic control as risk factors for cognitive decline in early old age: a post-hoc analysis of the Whitehall II cohort study. Lancet Diabetes and Endocrinology,the, 2014, 2, 228-235.	11.4	150
38	Atrial fibrillation as a risk factor for cognitive decline and dementia. European Heart Journal, 2017, 38, 2612-2618.	2.2	147
39	Traffic-related Air Pollution in Relation to Cognitive Function in Older Adults. Epidemiology, 2014, 25, 674-681.	2.7	144
40	Socioeconomic position, lifestyle habits and biomarkers of epigenetic aging: a multi-cohort analysis. Aging, 2019, 11, 2045-2070.	3.1	137
41	Prediction of cognition in Parkinson's disease with a clinical–genetic score: a longitudinal analysis of nine cohorts. Lancet Neurology, The, 2017, 16, 620-629.	10.2	131
42	Familial aggregation of Parkinson's disease. Neurology, 1999, 52, 1876-1876.	1.1	131
43	A Cross-Sectional and Longitudinal Study of the Relationship Between Walking Speed and Cognitive Function in Community-Dwelling Elderly People. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2009, 64A, 1058-1065.	3.6	125
44	Alcohol consumption and cognitive decline in early old age. Neurology, 2014, 82, 332-339.	1.1	125
45	Ideal Cardiovascular Health, Mortality, andÂVascular Events in Elderly Subjects. Journal of the American College of Cardiology, 2017, 69, 3015-3026.	2.8	125
46	Epidemiologic studies of environmental exposures in Parkinson's disease. Journal of the Neurological Sciences, 2007, 262, 37-44.	0.6	120
47	Association Between the Glu298Asp Polymorphism in the Endothelial Constitutive Nitric Oxide Synthase Gene and Brain Infarction. Stroke, 2000, 31, 1634-1639.	2.0	112
48	Education and occupations preceding Parkinson disease. Neurology, 2005, 65, 1575-1583.	1.1	111
49	Unhealthy behaviours and disability in older adults: Three-City Dijon cohort study. BMJ, The, 2013, 347, f4240-f4240.	6.0	111
50	Accelerometer assessed moderate-to-vigorous physical activity and successful ageing: results from the Whitehall II study. Scientific Reports, 2017, 7, 45772.	3.3	110
51	White matter lesions volume and motor performances in the elderly. Annals of Neurology, 2009, 65, 706-715.	5.3	109
52	Association between Parkinson's disease and polymorphisms in the nNOS and iNOS genes in a community-based case-control study. Human Molecular Genetics, 2003, 12, 79-86.	2.9	108
53	Postmenopausal Hormone Therapy and Risk of Stroke. Stroke, 2016, 47, 1734-1741.	2.0	108
54	NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases. Neurobiology of Aging, 2017, 57, 247.e9-247.e13.	3.1	108

#	Article	lF	Citations
55	Interaction Between ABCB1 and Professional Exposure to Organochlorine Insecticides in Parkinson Disease. Archives of Neurology, 2010, 67, 739-45.	4.5	106
56	Increased risk of coronary heart disease among individuals reporting adverse impact of stress on their health: the Whitehall II prospective cohort study. European Heart Journal, 2013, 34, 2697-2705.	2.2	103
57	Association between Parkinson's disease and the <i>HLAâ€ÐRB1</i> locus. Movement Disorders, 2012, 27, 1104-1110.	3.9	102
58	Nonfatal Cancer Preceding Parkinson's Disease: A Case-Control Study. Epidemiology, 2002, 13, 157-164.	2.7	96
59	Familial aggregation of Parkinson's disease: The Mayo Clinic family study. Annals of Neurology, 2004, 56, 495-502.	5. 3	96
60	Obesity phenotypes in midlife and cognition in early old age. Neurology, 2012, 79, 755-762.	1.1	94
61	Independent and joint effects of the <i>MAPT</i> and <i>SNCA</i> genes in Parkinson disease. Annals of Neurology, 2011, 69, 778-792.	5. 3	92
62	Decline in Fast Gait Speed as a Predictor of Disability in Older Adults. Journal of the American Geriatrics Society, 2015, 63, 1129-1136.	2.6	87
63	Chemical exposures and Parkinson's disease: A population-based case–control study. Movement Disorders, 2006, 21, 1688-1692.	3.9	85
64	Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study. Lancet Neurology, The, 2006, 5, 917-923.	10.2	83
65	Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson's disease. Nature Genetics, 2021, 53, 787-793.	21.4	82
66	Increased risk of essential tremor in firstâ€degree relatives of patients with Parkinson's disease. Movement Disorders, 2007, 22, 1607-1614.	3.9	81
67	Validity of family history data on PD. Neurology, 2003, 61, 11-17.	1.1	80
68	Common Carotid Artery Intima-Media Thickness, Carotid Plaques, and Walking Speed. Stroke, 2005, 36, 2198-2202.	2.0	74
69	Pooled analysis of iron-related genes in Parkinson's disease: Association with transferrin. Neurobiology of Disease, 2014, 62, 172-178.	4.4	74
70	Gait Speed and Decline in Gait Speed as Predictors of Incident Dementia. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, glw110.	3.6	74
71	Hypertension and lower walking speed in the elderly: the Three-City study. Journal of Hypertension, 2010, 28, 1506-1514.	0.5	73
72	Association of Parkinson's Disease and Its Subtypes with Agricultural Pesticide Exposures in Men: A Case–Control Study in France. Environmental Health Perspectives, 2015, 123, 1123-1129.	6.0	72

#	Article	IF	Citations
73	Case-control study of writer's cramp. Brain, 2009, 132, 756-764.	7.6	70
74	Projections of prevalence, lifetime risk, and life expectancy of Parkinson's disease (2010â€2030) in France. Movement Disorders, 2018, 33, 1449-1455.	3.9	68
75	Subjective cognitive complaints and mortality: Does the type of complaint matter?. Journal of Psychiatric Research, 2014, 48, 73-78.	3.1	63
76	Interaction between genes and environment in neurodegenerative diseases. Comptes Rendus - Biologies, 2007, 330, 318-328.	0.2	62
77	MRI atrophy of the caudate nucleus and slower walking speed in the elderly. NeuroImage, 2012, 60, 871-878.	4.2	62
78	S18Y polymorphism in the UCH‣1 gene and Parkinson's disease: Evidence for an ageâ€dependent relationship. Movement Disorders, 2003, 18, 130-137.	3.9	61
79	Abdominal obesity and lower gray matter volume: a Mendelian randomization study. Neurobiology of Aging, 2014, 35, 378-386.	3.1	61
80	Association between inflammatory biomarkers and all-cause, cardiovascular and cancer-related mortality. Cmaj, 2017, 189, E384-E390.	2.0	59
81	Risk of cancer after the diagnosis of Parkinson's disease: A historical cohort study. Movement Disorders, 2005, 20, 719-725.	3.9	57
82	Why Does Lung Function Predict Mortality? Results From the Whitehall II Cohort Study. American Journal of Epidemiology, 2010, 172, 1415-1423.	3.4	57
83	A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease. Neurobiology of Aging, 2011, 32, 548.e9-548.e18.	3.1	56
84	Contribution of cognitive performance and cognitive decline to associations between socioeconomic factors and dementia: A cohort study. PLoS Medicine, 2017, 14, e1002334.	8.4	56
85	Neuroticism and Cardiovascular Disease Mortality. Psychosomatic Medicine, 2012, 74, 596-603.	2.0	54
86	20-Year prevalence projections for dementia and impact of preventive policy about risk factors. European Journal of Epidemiology, 2013, 28, 493-502.	5.7	54
87	Association studies between haemochromatosis gene mutations and the risk of cardiovascular diseases. European Journal of Clinical Investigation, 2001, 31, 382-388.	3.4	53
88	Association of walking speed in late midlife with mortality: results from the Whitehall II cohort study. Age, 2013, 35, 943-952.	3.0	52
89	Pesticide Exposure and Depression Among Agricultural Workers in France. American Journal of Epidemiology, 2013, 178, 1051-1058.	3.4	49
90	Motor function in the elderly. Neurology, 2013, 81, 417-426.	1.1	48

#	Article	IF	CITATIONS
91	Risk of Cognitive Impairment or Dementia in Relatives of Patients With Parkinson Disease. Archives of Neurology, 2007, 64, 1458.	4.5	47
92	Polymorphism R92Q of the tumour necrosis factor receptor 1 gene is associated with myocardial infarction and carotid intima-media thickness – The ECTIM, AXA, EVA and GENIC Studies. European Journal of Human Genetics, 2004, 12, 213-219.	2.8	45
93	Blood Lipids in Brain Infarction Subtypes. Cerebrovascular Diseases, 2006, 22, 101-108.	1.7	45
94	Association of lung function with physical, mental and cognitive function in early old age. Age, 2011, 33, 385-392.	3.0	45
95	Myeloperoxidase polymorphisms in brain infarction. Association with infarct size and functional outcome. Atherosclerosis, 2003, 167, 223-230.	0.8	42
96	Genetic heterogeneity in hypokalemic periodic paralysis (hypoPP). Human Genetics, 1994, 94, 551-6.	3.8	41
97	Complex segregation analysis of Parkinson's disease: The Mayo Clinic Family Study. Annals of Neurology, 2006, 59, 788-795.	5.3	41
98	Change in Fast Walking Speed Preceding Death: Results From a Prospective Longitudinal Cohort Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2014, 69A, 354-362.	3.6	41
99	Trajectories of Unhealthy Behaviors in Midlife and Risk of Disability at Older Ages in the Whitehall II Cohort Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 1500-1506.	3.6	41
100	Past exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohort. Neurology, 2012, 79, 1615-1621.	1.1	40
101	Physical Activity and Adiposity Markers at Older Ages: Accelerometer Vs Questionnaire Data. Journal of the American Medical Directors Association, 2015, 16, 438.e7-438.e13.	2.5	40
102	Cigarette smoking and Parkinson's disease: A case–control study in a population characterized by a high prevalence of pesticide exposure. Movement Disorders, 2005, 20, 181-189.	3.9	37
103	Prediction Model of Parkinson's Disease Based on Antiparkinsonian Drug Claims. American Journal of Epidemiology, 2011, 174, 354-363.	3.4	37
104	Genetic susceptibility and ischaemic stroke. Current Opinion in Neurology, 1999, 12, 47-55.	3.6	37
105	Risk factors of multiple system atrophy: A caseâ€control study in French patients. Movement Disorders, 2008, 23, 797-803.	3.9	36
106	Predicting Survival of Patients with Amyotrophic Lateral Sclerosis at Presentation: A 15-Year Experience. Neurodegenerative Diseases, 2013, 12, 81-90.	1.4	36
107	The protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants. Neurobiology of Aging, 2014, 35, 266.e5-266.e14.	3.1	36
108	Agricultural activities and the incidence of Parkinson's disease in the general French population. European Journal of Epidemiology, 2017, 32, 203-216.	5.7	35

#	Article	IF	CITATIONS
109	No evidence of a longitudinal association between diurnal cortisol patterns and cognition. Neurobiology of Aging, 2014, 35, 2239-2245.	3.1	34
110	Characterization of Polymorphic Structure of Cathepsin G Gene. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1538-1543.	2.4	33
111	Mortality in patients with Parkinson's disease treated by stimulation of the subthalamic nucleus. Movement Disorders, 2007, 22, 257-261.	3.9	33
112	Improving survival in a large French ALS center cohort. Journal of Neurology, 2012, 259, 1788-1792.	3.6	33
113	Trajectories of the Framingham general cardiovascular risk profile in midlife and poor motor function later in life: The Whitehall II study. International Journal of Cardiology, 2014, 172, 96-102.	1.7	33
114	Parkinson's disease, smoking and family history. Journal of Neurology, 2000, 247, 793-798.	3.6	32
115	Cross-sectional association between homocysteine and motor function in the elderly. Neurology, 2006, 67, 985-990.	1.1	32
116	Populationâ€specific frequencies for <i>LRRK2</i> susceptibility variants in the genetic epidemiology of Parkinson's disease (GEOâ€PD) consortium. Movement Disorders, 2013, 28, 1740-1744.	3.9	30
117	Cumulative Associations Between Midlife Health Behaviors and Physical Functioning in Early Old Age: A 17â€Year Prospective Cohort Study. Journal of the American Geriatrics Society, 2014, 62, 1860-1868.	2.6	30
118	A diagnostic flow chart for <i>POLG-</i> related diseases based on signs sensitivity and specificity. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 646-654.	1.9	30
119	Examining the Reserve Hypothesis in Parkinson's Disease: A Longitudinal Study. Movement Disorders, 2019, 34, 1663-1671.	3.9	30
120	Blood Metal Levels and Amyotrophic Lateral Sclerosis Risk: A Prospective Cohort. Annals of Neurology, 2021, 89, 125-133.	5.3	29
121	Smoking and Parkinson disease. Neurology, 2018, 90, e583-e592.	1.1	27
122	Association of polymorphisms in the Tau and Saitohin genes with Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 478-480.	1.9	26
123	Body mass index trajectories and functional decline in older adults: Three-City Dijon cohort study. European Journal of Epidemiology, 2016, 31, 73-83.	5.7	26
124	Changing mortality for motor neuron disease in France (1968–2007): an age-period-cohort analysis. European Journal of Epidemiology, 2011, 26, 729-737.	5.7	25
125	Association of Parkinson's disease with industry sectors: a French nationwide incidence study. European Journal of Epidemiology, 2018, 33, 1101-1111.	5.7	25
126	Genome-wide Association and Meta-analysis of Age at Onset in Parkinson Disease. Neurology, 2022, 99, .	1.1	25

#	Article	IF	CITATIONS
127	The relation between type of farming and prevalence of Parkinson's disease among agricultural workers in five french districts. Movement Disorders, 2011, 26, 271-279.	3.9	24
128	Lack of Replication of the GRIN2A-by-Coffee Interaction in Parkinson Disease. PLoS Genetics, 2014, 10, e1004788.	3.5	24
129	Association of body mass index and waist circumference with successful aging. Obesity, 2014, 22, 1172-1178.	3.0	24
130	Mutation in DHP receptor alpha 1 subunit (CACLN1A3) gene in a Dutch family with hypokalaemic periodic paralysis Journal of Medical Genetics, 1995, 32, 44-47.	3.2	23
131	Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease. Neurobiology of Aging, 2011, 32, 2108.e1-2108.e5.	3.1	23
132	LOW DISEASE RISK IN RELATIVES OF NORTH AFRICAN LRRK2 PARKINSON DISEASE PATIENTS. Neurology, 2010, 75, 1118-1119.	1.1	22
133	Risk factors for spinal cord lesions in dystonic cerebral palsy and generalised dystonia. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 159-163.	1.9	22
134	Association study of the NEDD9 gene with the risk of developing Alzheimer's and Parkinson's disease. Human Molecular Genetics, 2008, 17, 2863-2867.	2.9	21
135	Non-Consent to a Wrist-Worn Accelerometer in Older Adults: The Role of Socio-Demographic, Behavioural and Health Factors. PLoS ONE, 2014, 9, e110816.	2.5	21
136	Prodromal symptoms of Parkinson's disease: Implications for epidemiological studies of disease etiology. Revue Neurologique, 2016, 172, 503-511.	1.5	21
137	Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinson's Disease. Journal of Parkinson's Disease, 2022, 12, 267-282.	2.8	21
138	Lipid-Lowering Drugs Associated With Slower Motor Decline in the Elderly Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2014, 69A, 199-206.	3.6	20
139	Pooled analysis of the <i>HLAâ€DRB1</i> by smoking interaction in Parkinson disease. Annals of Neurology, 2017, 82, 655-664.	5.3	20
140	The gait speed advantage of taller stature is lost with age. Scientific Reports, 2018, 8, 1485.	3.3	20
141	Increased Risk of Parkinson's Disease in Women after Bilateral Oophorectomy. Movement Disorders, 2021, 36, 1696-1700.	3.9	20
142	Risk of Suicide Among Patients With Parkinson Disease. JAMA Psychiatry, 2021, 78, 293.	11.0	19
143	Association between Blood Lead and Walking Speed in the National Health and Nutrition Examination Survey (NHANES 1999–2002). Environmental Health Perspectives, 2013, 121, 711-716.	6.0	18
144	Association of UV radiation with Parkinson disease incidence: A nationwide French ecologic study. Environmental Research, 2017, 154, 50-56.	7.5	18

#	Article	IF	Citations
145	Does midlife obesity really lower dementia risk?. Lancet Diabetes and Endocrinology,the, 2015, 3, 498.	11.4	17
146	Prevalence of fragile-X syndrome and FRAXE among children with intellectual disability in a Caribbean island, Guadeloupe, French West Indies. Journal of Intellectual Disability Research, 1998, 42, 81-89.	2.0	16
147	Case-control study of estrogen receptor gene polymorphisms in Parkinson's disease. Movement Disorders, 2002, 17, 509-512.	3.9	16
148	LRRK2: bridging the gap between sporadic and hereditary Parkinson's disease. Lancet Neurology, The, 2008, 7, 562-564.	10.2	16
149	Nonâ€replication of association for six polymorphisms from metaâ€analysis of genomeâ€wide association studies of Parkinson's disease: Largeâ€scale collaborative study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 220-228.	1.7	16
150	Restless Legs Syndrome and Cognitive Function: A Population-based Cross-sectional Study. American Journal of Medicine, 2015, 128, 1023.e33-1023.e39.	1.5	16
151	Association Between Occupational Exposure to Formaldehyde and Cognitive Impairment. Neurology, 2022, 98, .	1.1	16
152	Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study. Movement Disorders, 2022, 37, 857-864.	3.9	15
153	Bias in Association Studies Resulting from Gene-Environment Interactions and Competing Risks. American Journal of Epidemiology, 2002, 155, 265-272.	3.4	14
154	Impact of recommendations on the initial therapy of Parkinson's disease: A population-based study in France. Parkinsonism and Related Disorders, 2011, 17, 543-546.	2.2	14
155	Alphaâ ∈s ynuclein repeat variants and survival in Parkinson's disease. Movement Disorders, 2014, 29, 1053-1057.	3.9	14
156	Antidepressant medication use and trajectories of fasting plasma glucose, glycated haemoglobin, \hat{l}^2 -cell function and insulin sensitivity: a 9-year longitudinal study of the D.E.S.I.R. cohort. International Journal of Epidemiology, 2015, 44, 1927-1940.	1.9	14
157	The scientific bases to consider Parkinson's disease an occupational disease in agriculture professionals exposed to pesticides in France. Journal of Epidemiology and Community Health, 2016, 70, 319-321.	3.7	14
158	Nationwide incidence of motor neuron disease using the French health insurance information system database. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 426-433.	1.7	14
159	Testosterone and All-Cause Mortality in Older Men: The Role of Metabolic Syndrome. Journal of the Endocrine Society, 2018, 2, 322-335.	0.2	14
160	Plasminogen Activator Inhibitor Genotype and Brain Infarction. Circulation, 2001, 103, e13-4; author reply e13-4.	1.6	13
161	Incidence of Parkinson's disease in French women from the E3N cohort study over 27Âyears of follow-up. European Journal of Epidemiology, 2022, 37, 513-523.	5.7	11
162	Parkinson's disease polygenic risk score is not associated with impulse control disorders: A longitudinal study. Parkinsonism and Related Disorders, 2020, 75, 30-33.	2.2	10

#	Article	IF	Citations
163	Prevalence and incidence of young onset dementia and associations with comorbidities: A study of data from the French national health data system. PLoS Medicine, 2021, 18, e1003801.	8.4	10
164	Osteopontin gene variation and cardio/cerebrovascular disease phenotypes. Atherosclerosis, 2009, 206, 209-215.	0.8	9
165	Farming and incidence of motor neuron disease: French nationwide study. European Journal of Neurology, 2017, 24, 1191-1195.	3.3	9
166	French validation of the questionnaire for Impulsive-Compulsive Disorders in Parkinson's Diseaseâ€"Rating Scale (QUIP-RS). Parkinsonism and Related Disorders, 2019, 63, 117-123.	2.2	9
167	Structural brain lesions and restless legs syndrome: a cross-sectional population-based study. BMJ Open, 2014, 4, e005938.	1.9	8
168	Convergence of psychiatric symptoms and restless legs syndrome: A cross-sectional study in an elderly French population. Journal of Psychosomatic Research, 2020, 128, 109884.	2.6	8
169	Replication of a Novel Parkinson's Locus in a European Ancestry Population. Movement Disorders, 2021, 36, 1689-1695.	3.9	8
170	Association between occupational solvent exposure and cognitive performance in the French CONSTANCES study. Occupational and Environmental Medicine, 2020, 77, 223-230.	2.8	7
171	Trends in Drug Prescription Rates for Dementia: An Observational Population-Based Study in France, 2006–2014. Drugs and Aging, 2017, 34, 711-721.	2.7	6
172	Oestradiol level, oestrogen receptors, and mortality in elderly men: The threeâ€city cohort study. Clinical Endocrinology, 2018, 89, 514-525.	2.4	6
173	Age-dependent sex ratios of motor neuron disease. Neurology, 2018, 90, e1588-e1595.	1.1	5
174	Association of Reproductive History With Motor Function and Disability in Aging Women. Journal of the American Geriatrics Society, 2020, 68, 585-594.	2.6	5
175	Is the incidence of motor neuron disease higher in French military personnel?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 107-115.	1.7	4
176	The Interaction between <scp><i>HLAâ€DRB1</i></scp> and Smoking in Parkinson's Disease Revisited. Movement Disorders, 2022, 37, 1929-1937.	3.9	4
177	Longitudinal association between dopamine agonists and weight in Parkinson's disease. Parkinsonism and Related Disorders, 2020, 80, 158-164.	2.2	3
178	The South African Parkinson's Disease Study Collection. Movement Disorders, 2022, 37, 230-232.	3.9	3
179	Excess nonâ€psychiatric hospitalizations among employees with mental disorders: a 10â€year prospective study of the GAZEL cohort. Acta Psychiatrica Scandinavica, 2015, 131, 307-317.	4.5	2
180	Gait Decline. Hypertension, 2015, 66, 263-264.	2.7	2

ALEXIS ELBAZ

#	Article	IF	CITATIONS
181	Machine Learning-Based Prediction of Impulse Control Disorders in Parkinson's Disease From Clinical and Genetic Data. IEEE Open Journal of Engineering in Medicine and Biology, 2022, 3, 96-107.	2.3	2
182	In search of the causes of Parkinson's disease, seasons 1 to 4. European Journal of Epidemiology, 2011, 26, 505-509.	5.7	1
183	Testosterone Level and Cause-Specific Mortality in Older Men without Metabolic Syndrome. Epidemiology and Health, 2020, 42, e2020036.	1.9	1